DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
+32.6%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$439M
AUM Growth
+$439M
(+5.3%)
Cap. Flow
-$48.1M
Cap. Flow
% of AUM
-10.96%
Top 10 Holdings %
Top 10 Hldgs %
49.48%
Holding
86
New
10
Increased
12
Reduced
30
Closed
14
Top Buys
| 1 |
AtriCure
ATRC
|
$4.43M |
| 2 |
Perspective Therapeutics
CATX
|
$3.69M |
| 3 |
Insulet
PODD
|
$2.73M |
| 4 |
Larimar Therapeutics
LRMR
|
$2.52M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$2.44M |
Top Sells
| 1 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$15.2M |
| 2 |
IMGN
Immunogen Inc
IMGN
|
$5.74M |
| 3 |
SAGE
Sage Therapeutics
SAGE
|
$5.31M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$5.25M |
| 5 |
SPDR S&P Biotech ETF
XBI
|
$5.01M |
Sector Composition
| 1 | Healthcare | 86.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Immatics
IMTX
$662M
| $1.52M | 0.35% |
145,000
+40,000
| +38% | +$420K |
|
52
Neuronetics
STIM
$208M
| $1.49M | 0.34% |
313,717
| – | – |
|
53
Adicet Bio
ACET
$60.8M
| $1.41M | 0.32% |
+600,000
| New | +$1.41M |
|
|
AUTL
54
Autolus Therapeutics
AUTL
$383M
| $1.38M | 0.31% |
216,667
+25,597
| +13% | +$163K |
|
|
SLRN
55
DELISTED
ACELYRIN
SLRN
| $1.37M | 0.31% |
202,587
-168,613
| -45% | -$1.14M |
|
|
ITOS
56
DELISTED
iTeos Therapeutics
ITOS
| $1.34M | 0.31% |
98,560
| – | – |
|
57
Mineralys Therapeutics
MLYS
$1.94B
| $1.16M | 0.26% |
90,000
+74,800
| +492% | +$966K |
|
58
Compugen
CGEN
$133M
| $1.11M | 0.25% |
430,202
+225,000
| +110% | +$581K |
|
59
Immunovant
IMVT
$2.91B
| $950K | 0.22% |
29,416
-11,326
| -28% | -$366K |
|
60
Acrivon Therapeutics
ACRV
$42.2M
| $939K | 0.21% |
131,351
| – | – |
|
61
Aprea Therapeutics
APRE
$8.91M
| $918K | 0.21% |
+137,174
| New | +$918K |
|
62
PolyPid
PYPD
$54.4M
| $853K | 0.19% |
+185,446
| New | +$853K |
|
|
SYRS
63
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $727K | 0.17% |
135,850
-79,035
| -37% | -$423K |
|
|
ADAP
64
Adaptimmune Therapeutics
ADAP
$13.9M
| $539K | 0.12% |
341,064
-10,000
| -3% | -$15.8K |
|
65
Masimo
MASI
$7.43B
| $441K | 0.1% |
3,000
| – | – |
|
|
NVRO
66
DELISTED
NEVRO CORP.
NVRO
| $404K | 0.09% |
28,000
| – | – |
|
67
Karyopharm Therapeutics
KPTI
$61.4M
| $291K | 0.07% |
12,845
| – | – |
|
|
VIGL
68
DELISTED
Vigil Neuroscience
VIGL
| $245K | 0.06% |
71,815
| – | – |
|
69
Compass Therapeutics
CMPX
$466M
| $231K | 0.05% |
116,882
| – | – |
|
70
Spero Therapeutics
SPRO
$117M
| $215K | 0.05% |
125,000
| – | – |
|
71
Alto Neuroscience
ANRO
$97.7M
| $154K | 0.03% |
+10,000
| New | +$154K |
|
72
Amylyx Pharmaceuticals
AMLX
$877M
| – | – |
-122,547
| Closed | -$1.8M |
|
73
argenx
ARGX
$44.2B
| – | – |
-3,600
| Closed | -$1.37M |
|
74
Cullinan Oncology
CGEM
$456M
| – | – |
-127,284
| Closed | -$1.3M |
|
|
ELEV
75
DELISTED
Elevation Oncology
ELEV
| – | – |
-450,000
| Closed | -$242K |
|